Herd immunity and pneumococcal conjugate vaccine: A quantitative model

• Published in: Vaccine Vol. 25; no. 29; pp. 5390 - 5398
• Main Authors: Haber, Michael, Barskey, Albert, Baughman, Wendy, Barker, Lawrence, Whitney, Cynthia G, Shaw, Kate M, Orenstein, Walter, Stephens, David S
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 20-07-2007; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Allergy and Immunology; Applied microbiology; Bacteriology; Biological and medical sciences; Child; Child, Preschool; Children & youth; Conjugate vaccine; Fundamental and applied biological sciences. Psychology; Georgia - epidemiology; Heptavalent Pneumococcal Conjugate Vaccine; Herd immunity; Humans; Immunity, Herd; Immunization; Incidence; Infant; Laboratories; Meningitis; Meningococcal Vaccines - immunology; Microbiology; Middle Aged; Miscellaneous; Pneumococcal Infections - epidemiology; Pneumococcal Infections - immunology; Pneumococcal Infections - microbiology; Pneumococcal Vaccines - immunology; Pneumococci; Pneumonia; Serotyping; Streptococcus pneumoniae; Streptococcus pneumoniae - classification; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Georgia; Atlanta Georgia; United States > US; Herd immunity; Conjugate vaccine; Pneumococci; Streptococcaceae; Bacteria; Micrococcales; Models; Vaccine; Quantitative analysis; Streptococcus pneumoniae
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2007.04.088

Abstract Invasive pneumococcal disease in older children and adults declined markedly after introduction in 2000 of the pneumococcal conjugate vaccine for young children. An empirical quantitative model was developed to estimate the herd (indirect) effects on the incidence of invasive disease among persons ≥5 years of age induced by vaccination of young children with 1, 2, or ≥3 doses of the pneumococcal conjugate vaccine, Prevnar® (PCV7), containing serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. From 1994 to 2003, cases of invasive pneumococcal disease were prospectively identified in Georgia Health District-3 (eight metropolitan Atlanta counties) by Active Bacterial Core surveillance (ABCs). From 2000 to 2003, vaccine coverage levels of PCV7 for children aged 19–35 months in Fulton and DeKalb counties (of Atlanta) were estimated from the National Immunization Survey (NIS). Based on incidence data and the estimated average number of doses received by 15 months of age, a Poisson regression model was fit, describing the trend in invasive pneumococcal disease in groups not targeted for vaccination (i.e., adults and older children) before and after the introduction of PCV7. Highly significant declines in all the serotypes contained in PCV7 in all unvaccinated populations (5–19, 20–39, 40–64, and >64 years) from 2000 to 2003 were found under the model. No significant change in incidence was seen from 1994 to 1999, indicating rates were stable prior to vaccine introduction. Among unvaccinated persons 5+ years of age, the modeled incidence of disease caused by PCV7 serotypes as a group dropped 38.4%, 62.0%, and 76.6% for 1, 2, and 3 doses, respectively, received on average by the population of children by the time they are 15 months of age. Incidence of serotypes 14 and 23F had consistent significant declines in all unvaccinated age groups. In contrast, the herd immunity effects on vaccine-related serotype 6A incidence were inconsistent. Increasing trends of non-vaccine serotypes, in particular 19A, were noted in most unvaccinated age groups, but these increases were substantially smaller than the concurrent decreases among the vaccine serotypes. Also, the model estimated PCV7 to have a greater ( p = 0.014) indirect impact on the incidence of invasive pneumococcal disease caused by all vaccine serotypes among African-Americans of all ages than for whites. Thus, conjugate vaccines may be able to induce herd effects even in situations where vaccine coverage is far from complete or with schedules using fewer than 3 or 4 doses. Because the model was based on incidence rates and PCV7 coverage in Atlanta, our findings should be validated in other geographic areas.